X4 Pharmaceuticals (XFOR) Invested Capital (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Invested Capital for 10 consecutive years, with $232.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital rose 190.95% year-over-year to $232.2 million; the trailing twelve-month figure through Jun 2026 stood at $232.2 million (up 190.95% YoY), and the FY2025 full-year result was $262.6 million, up 169.11% from the prior year.
• Invested Capital retreated to $232.2 million in Q2 2026 per XFOR's latest filing, from $245.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $262.6 million in Q4 2025 and bottomed at $56.0 million in Q1 2024.
• Historically, Invested Capital has averaged $127.9 million across 5 years, with a median of $107.0 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Invested Capital tumbled 52.91% in 2025, then jumped 190.95% in 2026.
• Over 5 years, Invested Capital stood at $107.9 million in 2022, then fell by 1.64% to $106.1 million in 2023, then fell by 8.03% to $97.6 million in 2024, then jumped by 169.11% to $262.6 million in 2025, then slipped by 11.57% to $232.2 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $232.2 million, $245.0 million, and $262.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.